Key result
This literature review examines the timing of thrombophilia screening in patients taking DOACs, the effect of DOACs on thrombophilia tests, and the safety of DOACs in thrombophilia.
Why the study?
Guidelines regarding when and how to test for underlying thrombophilia, particularly in patients established on direct oral anticoagulants, remain unclear.
This literature review examines the timing of thrombophilia screening in patients on DOACs, the impact of DOACs on test results, and the safety and efficacy of DOACs in thrombophilia.
Guidelines for thrombophilia testing on DOACs remain unclear; leaves open standardized screening strategies in VTE.
Venous thromboembolism (VTE) is increasingly recognised in primary and secondary care practice. The arrival of direct oral anticoagulants (DOACs) has made the management of VTE easier and more convenient. Some patients established on DOACs may need screening for underlying thrombophilias as certain thrombophilic conditions are known to confer a higher thrombosis risk, although the guidelines for when and how to test for a thrombophilia, especially in a patient taking a DOAC, are unclear. This literature review aims to examine when thrombophilia screening should take place in a patient already taking a DOAC, the effect of DOACs on thrombophilia tests, and analyse whether DOACs are safe and effective in both inherited and acquired thrombophilias.
No takes yet. Share an insight, caveat, or question.
Darlow et al. (2021) conducted a review in Venous thromboembolism (VTE) and thrombophilia. Thrombophilia screening and direct oral anticoagulants (DOACs) was evaluated. This literature review examines the timing of thrombophilia screening in patients taking DOACs, the effect of DOACs on thrombophilia tests, and the safety of DOACs in thrombophilia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: